Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$12.52
+0.12 (+0.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $126.5M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.2B
P/E
89.4x
↑EV/EBITDA
30.1x
↑ROE
3.8%
↑Gross Margin
57.4%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.8%
FCF CAGR
—
FCF margin
5.8%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $827.1M · net income $65.1M · FCF $47.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $827.1M | $827.1M | $774.8M | $691.5M | $785.2M |
| Net Income | $65.1M | $65.1M | $76.7M | $32.7M | $98.4M |
| EBITDA | $165.7M | $165.7M | $179.9M | $125.8M | $197.3M |
| EPS | 0.16 | 0.16 | 0.18 | 0.08 | 0.24 |
| Gross Margin | 57.4% | 57.4% | 57.3% | 55.0% | 59.3% |
| Operating Margin | 8.4% | 8.4% | 11.0% | 5.9% | 15.2% |
| Net Margin | 7.9% | 7.9% | 9.9% | 4.7% | 12.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 4.68 | 4.68 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $47.7M | $47.7M | $145.6M | $126.5M | $-47.6M |
| Returns | |||||
| ROE | 3.8% | 3.8% | 4.6% | 2.0% | 6.1% |
| Valuation | |||||
| P/E | 89.43 | 89.43 | 68.05 | 213.41 | 85.54 |
| EV/EBITDA | 30.14 | 30.14 | 26.49 | 51.98 | 40.10 |
| P/B | 3.09 | 3.09 | 3.15 | 4.31 | 5.23 |
| Growth & Yield | |||||
| Revenue Growth | 6.8% | 6.8% | 12.0% | -11.9% | — |
| EPS Growth | -15.1% | -15.1% | 134.6% | -67.9% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
92.4%
EPS terminal req.
$1.11
Spread vs growth
-107.6%
5Y implied EPS CAGR
53.9%
EPS terminal req.
$1.34
Spread vs growth
-69.0%
10Y implied EPS CAGR
30.1%
EPS terminal req.
$2.16
Spread vs growth
-45.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.1%
Start / end P/E
77.2x → 80.3x
EPS bridge
0.18 → 0.16
Residual
-0.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.